Morgan Stanley restated their overweight rating on shares of REGENXBIO Inc. (NASDAQ:RGNX) in a research report released on Thursday, MarketBeat reports. They currently have a $34.00 target price on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. BidaskClub upgraded shares of REGENXBIO from a hold rating to a buy rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of REGENXBIO from a hold rating to a buy rating and set a $23.00 price objective for the company in a research report on Saturday, August 12th. Chardan Capital boosted their price objective on shares of REGENXBIO from $75.00 to $85.00 and gave the company a buy rating in a research report on Thursday. Evercore ISI began coverage on shares of REGENXBIO in a research report on Wednesday, August 16th. They set an outperform rating and a $25.00 price objective for the company. Finally, Bank of America Corporation upped their target price on shares of REGENXBIO from $29.00 to $33.00 and gave the stock a buy rating in a research report on Thursday, September 21st. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and an average price target of $40.57.

Shares of REGENXBIO (NASDAQ RGNX) traded up $0.70 during mid-day trading on Thursday, reaching $27.50. 238,500 shares of the company’s stock were exchanged, compared to its average volume of 330,076. REGENXBIO has a 52-week low of $16.30 and a 52-week high of $36.10.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.04. The business had revenue of $1.34 million for the quarter. REGENXBIO had a negative net margin of 764.06% and a negative return on equity of 39.33%. equities analysts expect that REGENXBIO will post -2.63 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/13/morgan-stanley-reaffirms-overweight-rating-for-regenxbio-inc-rgnx.html.

In related news, insider Kenneth T. Mills sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $20.05, for a total value of $130,325.00. Following the completion of the sale, the insider now owns 105,500 shares in the company, valued at approximately $2,115,275. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $32.62, for a total transaction of $326,200.00. Following the completion of the sale, the insider now owns 98,730 shares of the company’s stock, valued at approximately $3,220,572.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 210,040 shares of company stock valued at $5,874,639. Company insiders own 17.00% of the company’s stock.

Several large investors have recently modified their holdings of RGNX. Parametric Portfolio Associates LLC lifted its position in shares of REGENXBIO by 169.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 40,928 shares of the biotechnology company’s stock valued at $790,000 after acquiring an additional 25,729 shares in the last quarter. American International Group Inc. lifted its position in shares of REGENXBIO by 7.1% in the 1st quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock valued at $241,000 after acquiring an additional 822 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of REGENXBIO by 23.2% in the 1st quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock valued at $18,942,000 after acquiring an additional 184,700 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of REGENXBIO by 3.6% in the 1st quarter. Geode Capital Management LLC now owns 171,346 shares of the biotechnology company’s stock valued at $3,306,000 after acquiring an additional 5,949 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of REGENXBIO by 6.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 73,724 shares of the biotechnology company’s stock valued at $1,423,000 after acquiring an additional 4,275 shares in the last quarter. Institutional investors and hedge funds own 73.13% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.